ANI Pharmaceuticals launches generic version of Cymbalta
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts ANIP Hot Sheet
Join SI Premium – FREE
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced the launch of Duloxetine Delayed-Release Capsules in 20, 30, and 60 mg doses, a generic version of the branded drug Cymbalta.
U.S. annual sales for Duloxetine Delayed-Release Capsules totaled approximately $247 million, based on August 2026 moving annual total data from IQVIA.
Nikhil Lalwani, President and Chief Executive Officer of ANI Pharmaceuticals, said the launch provides "another alternative of a widely used therapy in a limited player market to assure stable supply."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Moderna shares plunge on cancer vaccine data leak
- Active options: AMD MRNA NFLX GOOGL IREN ORCL MSTR PLTR AVGO JBLU HOOD
- Trump Called Musk and Asked Him to Lift Ukraine Starlink Restrictions -- WSJ
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
Maynard Um, Mark Zuckerberg, Irina Koffler, FDA, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
